Summary of all procedures
| No./Age/Sex | Indication | Lesion Site | Procedure | Stent Type | Concomitant Medication | Stenosis Pre/Post | Follow-Up Modality/Duration | Restenosis |
|---|---|---|---|---|---|---|---|---|
| 1/69/M | ↓ rCBF | Left VA | PTA | − | − | 95/55 | TCD/88 months | No |
| 2/51/F | ↓ rCBF | Right ICA | PTA | − | − | 85/70 | TCD/72 months | No |
| 3/69/M | Medical failure | BA | PTA | − | − | 80/50 | TCD/36 months | Yes |
| 4/61/M | ↓ rCBF | Right ICA | Primary stenting | AVE | IV abciximab (bolus 20 mg) | 60/0 | TCD/68 months | No |
| 5a/64/M | Medical failure | Left MCA | PTA | − | − | 64/39 | TCD/7 months (confirmed DSA) | Yes |
| 5b | Medical failure | PTA | − | IV abciximab (bolus 10 mg) | 77/0 | TCD/36 months (confirmed MRA, DSA) | Yes | |
| 5c | Medical failure | Primary stenting | Liberté | − | 90/0 | TCD/3 months | No | |
| 6/53/F | Medical failure | Left MCA | PTA | − | − | 73/68 | TCD/49 months | No |
| 7/60/M | ↓ rCBF | Left ICA | PTA & stenting | INX | − | 83/0 | TCD/45 months | No |
| 8/73/M | Medical failure | Right MCA | Primary stenting | INX | IV abciximab (bolus 10 mg) | 99/50 | − | − |
| 9/76/M | Medical failure | Left ICA | Primary stenting | INX | − | 83/0 | − | − |
| 10/47/F | Medical failure | Left MCA | PTA | − | − | 99/17 | TCD/7 months (confirmed MRA) | Yes |
| 11/29/M | Medical failure | Left MCA | PTA & stenting | INX | IA urokinase (0.5 MIU/1 hour) | 57/0 | TCD/40 months | No |
| 12/45/M | ↓ rCBF | Left MCA | Primary stenting | INX | IV abciximab (bolus 10 mg) | 75/50 | TCD/2 months (confirmed DSA) | Yes |
| 13/59/M | Medical failure | BA | Primary stenting | INX | IV abciximab (bolus 10 mg) | 99/23 | TCD/22 months | No |
| 14/41/M | ↓ rCBF | Left MCA | Primary stenting | Cerebrence | − | 74/10 | TCD/25 months | No |
| 15/51/M | ↓ rCBF | Right ICA | Primary stenting | INX | − | 75/0 | TCD/7 months (confirmed MRA) | Yes |
| 16/65/M | ↓ rCBF | Left ICA | Primary stenting | INX | − | 67/50 | TCD/24 months | Yes |
| 17/63/M | Medical failure | Left ICA | Primary stenting | Cerebrence | − | 65/0 | TCD/1 month | No |
| 18/69/M | Medical failure | Left VA | Primary stenting | Liberté | − | 99/0 | TCD/28 months | No |
| 19/37/M | Medical failure | Right MCA | Primary stenting | TAXUS | IV abciximab (bolus 20 mg) | 90/0 | TCD/2.5 months (confirmed MRA, DSA) | Yes (in-stent thrombosis) |
| 20/66/F | Medical failure | Left MCA | Primary stenting | TAXUS | − | 90/0 | TCD/4 months | No |
| 21/57/F | Medical failure | Left ICA | Primary stenting | Liberté | − | 80/60 | − | − |
| 22/73/F | Medical failure | BA | n.s. | − | IV abciximab (bolus 5 mg) | 99 | − | − |
| 23/57/M | Medical failure | BA | n.s. | − | IV abciximab (bolus 20 mg) | 99 | − | − |
| 24/72/F | Medical failure | Left MCA | Primary stenting | TAXUS | − | 70/0 | MRA/3 months | No |
| 25/61/M | Medical failure | Right VA | Primary stenting | Liberté | − | 99/10 | − | − |
| 26/54/M | Medical failure | BA | Primary stenting | TAXUS | − | 99/10 | TCD/13 months | No |
| 27/63/M | Medical failure | BA | Primary stenting | Liberté | IV abciximab (bolus 20 mg, infusion 7.2 mg/12 hours) IA tPA (6 mg) | 82/0 | TCD/1 month | Yes |
| 28/41/M | ↓ rCBF | Right MCA | Primary stenting | TAXUS | − | 90/0 | TCD/18 months | No |
| 29/67/M | ↓ rCBF | Left ICA | Primary stenting | Liberté | − | 80/60 | TCD/3 days (confirmed MRA) | Yes (in-stent thrombosis) |
| 30/42/M | Medical failure | BA | PTA | − | − | 80/60 | − | − |
| 31/74/M | ↓ rCBF | Right MCA | PTA | − | IV abciximab (bolus 17.5 mg, infusion 6.3 mg/12 hours) | 72/30 | TCD/12 months | No |
| 32/69/M | Medical failure | Left VA | PTA | − | − | 70/40 | TCD/9 months | No |
| 33/66/M | ↓ rCBF | BA | n.s. | − | IV abciximab (bolus 20 mg, infusion 7.2 mg/12 hours) | 99 | − | − |
| 34/41/F | ↓ rCBF | Right MCA | PTA | − | − | 50/25 | TCD/10 months | No |
| 35/41/M | ↓ rCBF | BA | PTA | − | IV abciximab (bolus 20 mg, infusion 7.2 mg/12 hours) | 90/50 | − | − |
| 36/66/M | Medical failure | BA | PTA & stenting | Liberté | − | 61/25 | TCD/10 months | No |
Note:—↓ rCBF indicates impaired regional cerebral blood flow; n.s., not successful; PTA, percutaneous transluminal angioplasty; MCA, middle cerebral artery; ICA, internal carotid artery; VA, vertebral artery; BA, basilar artery; MRA, MR angiography; DSA, digital subtraction angiography; TCD, transcranial Doppler; IA, intra-arterial; IV, intravenous; tPA, tissue plasminogen activator.